Tragara inks new CEO; announces name change

Tragara Pharmaceuticals Inc. announced Thursday it has appointed Scott Megaffin as its new CEO and member of the board of directors, effective immediately.

Megaffin will replace Tom Estok, who will remain in an advisory capacity and continue in his role on the board of directors.

The addition of the company’s new CEO comes during the company’s name change to Adastra Pharmaceuticals Inc. As part of the new branding strategy, Adastra has expanded its operations beyond San Diego with a new Princeton-based office.

“Scott has the right experience to drive forward all of the Adastra strategic imperatives and continued program advancement of TG02,” Dennis Podlesak, Adastra chairman and partner of Domain Associates, said. “The board would like to acknowledge and thank Tom for his vision and dedication in getting us to this point.”

Prior to joining the company, Megaffin was president of Churchill Pharmaceuticals LLC. Before that, he held a variety of roles at Onconova Therapeutics Inc., Cephalon Inc., Adolor Corp., Yamounchi and Bristol-Myers Squibb Co.